Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

602 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective study.
Okuji T, Iwama S, Kobayashi T, Yasuda Y, Ito M, Yamagami A, Ando M, Hase T, Shibata H, Hatta T, Zhou X, Onoue T, Kawaguchi Y, Miyata T, Sugiyama M, Hagiwara D, Suga H, Banno R, Ando Y, Hashimoto N, Arima H. Okuji T, et al. Among authors: hase t. Nagoya J Med Sci. 2024 Aug;86(3):452-463. doi: 10.18999/nagjms.86.3.452. Nagoya J Med Sci. 2024. PMID: 39355355 Free PMC article.
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis.
Yamamoto T, Mizuno K, Ito T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Ishikawa T, Kanamori A, Yasuda S, Toyoda H, Yokota K, Hase T, Nishio N, Maeda O, Ishii M, Sone M, Ando Y, Akiyama M, Ishigami M, Kawashima H. Yamamoto T, et al. Among authors: hase t. Invest New Drugs. 2023 Jun;41(3):512-521. doi: 10.1007/s10637-023-01366-3. Epub 2023 May 12. Invest New Drugs. 2023. PMID: 37171720
Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L).
Ozawa Y, Koh Y, Hase T, Chibana K, Kaira K, Okishio K, Ichihara E, Murakami S, Shimokawa M, Yamamoto N. Ozawa Y, et al. Among authors: hase t. Ther Adv Med Oncol. 2024 Jan 27;16:17588359231225046. doi: 10.1177/17588359231225046. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38282663 Free PMC article.
Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma.
Tai MC, Bantis LE, Parhy G, Kato T, Tanaka I, Chow CW, Fujimoto J, Behrens C, Hase T, Kawaguchi K, Fahrmann JF, Ostrin EJ, Yokoi K, Chen-Yoshikawa TF, Hasegawa Y, Hanash SM, Wistuba II, Taguchi A. Tai MC, et al. Among authors: hase t. Int J Mol Sci. 2024 Feb 16;25(4):2331. doi: 10.3390/ijms25042331. Int J Mol Sci. 2024. PMID: 38397007 Free PMC article.
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data.
Terai H, Soejima K, Shimokawa A, Horinouchi H, Shimizu J, Hase T, Kanemaru R, Watanabe K, Ninomiya K, Aragane N, Yanagitani N, Sakata Y, Seike M, Fujimoto D, Kasajima M, Kubo A, Kusumoto S, Oyamada Y, Fujiwara K, Mori M, Hashimoto M, Shingyoji M, Kodani M, Sakamoto J, Agatsuma T, Kashiwabara K, Inomata M, Tachihara M, Tanaka K, Hayashihara K, Koyama N, Matsui K, Minato K, Jingu D, Sakashita H, Hara S, Naito T, Okada A, Tanahashi M, Sato Y, Asano K, Takeda T, Nakazawa K, Harada T, Shibata K, Kato T, Miyaoka E, Yoshino I, Gemma A, Mitsudomi T. Terai H, et al. Among authors: hase t. JTO Clin Res Rep. 2022 Sep 1;3(11):100404. doi: 10.1016/j.jtocrr.2022.100404. eCollection 2022 Nov. JTO Clin Res Rep. 2022. PMID: 36275911 Free PMC article.
Transcriptomic profiling of a late recurrent nuclear protein in testis carcinoma of the lung 14 years after the initial operation: a case report.
Kato T, Oyamatsu H, Hanamatsu Y, Huang H, Okado S, Imamura Y, Nomata Y, Watanabe H, Kadomatsu Y, Ueno H, Nakamura S, Mizuno T, Hase T, Takeuchi T, Chen-Yoshikawa TF. Kato T, et al. Among authors: hase t. Transl Lung Cancer Res. 2024 Jul 30;13(7):1756-1762. doi: 10.21037/tlcr-24-259. Epub 2024 Jul 11. Transl Lung Cancer Res. 2024. PMID: 39118893 Free PMC article.
Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: a prospective study with immortal time bias correction.
Suzuki K, Kobayashi T, Izuchi T, Otake K, Ando M, Handa T, Miyata T, Sugiyama M, Onoue T, Hagiwara D, Suga H, Banno R, Hase T, Inoue M, Ishii M, Arima H, Iwama S. Suzuki K, et al. Among authors: hase t. Front Endocrinol (Lausanne). 2024 Nov 7;15:1490042. doi: 10.3389/fendo.2024.1490042. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39574956 Free PMC article.
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R, Buchmeier EL, Chang JW, Shiraishi Y, Goksu SS, Badzio A, Shi A, Daniel DB, Hoa NTT, Zemanova M, Mann H, Gowda H, Jiang H, Senan S; ADRIATIC Investigators. Cheng Y, et al. N Engl J Med. 2024 Oct 10;391(14):1313-1327. doi: 10.1056/NEJMoa2404873. Epub 2024 Sep 13. N Engl J Med. 2024. PMID: 39268857 Clinical Trial.
602 results